Vaginal Health, Women's Health
Conditions
Keywords
Probiotic Supplement, Urinary Tract Health
Brief summary
This virtual single-group clinical trial aims to evaluate the effects of the Good Girl Probiotics supplement on vaginal health. Participants will take one capsule of the probiotic supplement daily for eight weeks. They will complete questionnaires at Baseline, after the first dose, and at the end of Weeks 2, 4, 6, and 8 to assess changes in vaginal pH, vaginal health, and urinary tract health.
Interventions
DIETARY_SUPPLEMENTGood Girl Probiotics
Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
Sponsors
Citruslabs
Love Wellness
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female at birth. * Aged 18+. * Interested in supporting a balanced vaginal pH, vaginal health, and urinary tract health. * Regularly experience symptoms of an unbalanced vagina, including an atypical smell, discharge, itching, swelling, irritation, pain during sex, and/or burning sensation while urinating. * Willing to avoid using products or medications that target vaginal or urinary tract health infections. * Willing to avoid other probiotics. * Able to follow the study protocol.
Exclusion criteria
* Two or more bladder infections in six months or three or more infections in a year. * Recent surgeries or invasive treatments within the last six months. * Use of products or medications targeting vaginal or urinary tract health in the last 12 weeks. * Known allergies to the product ingredients. * Chronic health conditions impacting participation. * Pregnant, breastfeeding, or trying to conceive. * History of substance abuse. * Current or former smoker within the past six months. * Participation in another clinical trial. * Diagnosed vaginal or pelvic conditions. * Use of vaginal-related birth control (NuvaRing, IUD). * Changes in hormonal birth control in the last three months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vaginal and Urinary Tract Health and Balance | Baseline, Week 2, Week 4, Week 6, Week 8 | Assessment of vaginal and urinary tract health and balance through questionnaires completed by participants at Baseline, after the first dose, and at the end of Weeks 2, 4, 6, and 8. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaginal Environment and Odor | Baseline, Week 2, Week 4, Week 6, Week 8 | Assessment of the vaginal environment and odor through questionnaires completed by participants at Baseline, after the first dose, and at the end of Weeks 2, 4, 6, and 8. |
Countries
United States
Outcome results
None listed